'BioSimilar' drug approved to treat certain types of anemia

(HealthDay)—Retacrit (epoetin alfa-epbx) has been approved by the U.S. Food and Drug Administration as the first "biosimilar" to the anemia drugs Epogen and Procrit.

A biosimilar, derived from a living organism, has been proven to be "highly similar" to a product that's already been approved by the FDA. It's also been shown to have no "clinically meaningful differences" in its safety, purity and potency than the prior approved drugs, the agency explained Tuesday in a news release.

"Biosimilars can provide greater access to treatment options for patients, increasing competition and potentially lowering costs," said Leah Christi, Ph.D., director of the agency's Therapeutic Biologics and Biosimilars Staff.

Epogen/Procrit are approved to treat anemia caused by , chemotherapy or use of certain drugs to treat infection with HIV, the virus that causes AIDS.

Previously noted side effects of epoetin alfa include: , joint pain, , fever, dizziness, blood vessel blockage and respiratory infection, the FDA said.

As with Epogen/Procrit, Retacrit's label includes a boxed warning about increased risk of death, heart problems, stroke, tumor growth, high blood pressure, seizures and serious allergic reactions.

Retactrit is produced by Hospira Inc., a unit of New York City-based Pfizer.


Explore further

FDA approves biosimilar ogivri for breast, stomach cancers

More information: Learn more from the FDA.

Copyright © 2018 HealthDay. All rights reserved.

Citation: 'BioSimilar' drug approved to treat certain types of anemia (2018, May 15) retrieved 19 January 2019 from https://medicalxpress.com/news/2018-05-biosimilar-drug-anemia.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
2 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more